Breaking News Bar

Business News and Information

CEO: Aratana is focused on 'near-term value enhancement,' but R&D will continue

Craig Tooman, the new CEO of Aratana Therapeutics Inc., said that the company is focused on "near-term value enhancement," but that a promising new drug will be a focus of R&D expenses in 2019.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear